Stock Analysis
- United Kingdom
- /
- Life Sciences
- /
- AIM:DXRX
Diaceutics Full Year 2023 Earnings: Revenues In Line With Expectations
Diaceutics (LON:DXRX) Full Year 2023 Results
Key Financial Results
- Revenue: UK£23.7m (up 22% from FY 2022).
- Net loss: UK£1.75m (down by 341% from UK£724.0k profit in FY 2022).
All figures shown in the chart above are for the trailing 12 month (TTM) period
Diaceutics Meets Expectations
Revenue was in line with analyst estimates.
Looking ahead, revenue is forecast to grow 21% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Life Sciences industry in Europe.
Performance of the market in the United Kingdom.
The company's shares are up 18% from a week ago.
Balance Sheet Analysis
While earnings are important, another area to consider is the balance sheet. We have a graphic representation of Diaceutics' balance sheet and an in-depth analysis of the company's financial position.
Valuation is complex, but we're helping make it simple.
Find out whether Diaceutics is potentially over or undervalued by checking out our comprehensive analysis, which includes fair value estimates, risks and warnings, dividends, insider transactions and financial health.
View the Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
About AIM:DXRX
Diaceutics
A diagnostic commercialisation company, provides data, data analytics, and implementation services for pharmaceutical companies worldwide.
Flawless balance sheet and good value.